Professor of Clinical Genetics
- Consultant Physician
Chromatin remodelling factors in human genetic disease.
The principal aim of the group is to characterise the ATRX protein; germline mutations in the underlying gene give rise to a severe X-linked form of syndromal intellectual disability one feature of which is alpha thalassaemia. We run a clinical and molecular diagnostic service through which we have collected over 200 affected families. We identify the underlying mutations and through microarray gene expression analysis, methylation studies, enzyme assays and protein structure studies we are defining their functional consequences. This clinical work also informs our research which is to both understand the function of this protein and understand how mutations lead to disease. Recent work has shown that ATRX with the histone chaperone DAXX remodels chromatin by replacing canonical histones with the histone variant H3.3 and that this role is important in maintaining epigenetic memory and patterns of gene expression.
In the last 5 years it has been shown that ATRX acts as a tumour suppressor. Somatic mutations in ATRX are observed in a group of cancers which maintain their telomere length not by reactivating telomerase as is seen in 85% of cancers, but using homology directed repair, a process known as Alternative Lengthening of Telomeres (ALT). We have shown that re-expressing ATRX leads to repression of ALT and this has opened up a new area of research which we are exploring in collaboration with Dr David Clynes (Dept of Oncology)
Phenotypic and molecular characterization of a serum-free miniature erythroid differentiation system suitable for high-throughput screening and single-cell assays.
Mettananda S. et al, (2018), Exp Hematol, 60, 10 - 20
Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
Mettananda S. et al, (2017), Nat Commun, 8
The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats.
Nguyen DT. et al, (2017), EMBO Rep, 18, 914 - 928
Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia.
Mettananda S. et al, (2017), Haematologica, 102, e80 - e84
Genetic dissection of the α-globin super-enhancer in vivo.
Hay D. et al, (2016), Nat Genet, 48, 895 - 903